Yang H,Bi Y,Xue L,et al. Multifaceted modulation of SIRT1 in cancer and inflammation[J]. Crit Rev On-cog,2015,20(1-2):49-64.
[2]
Zhu L,Chiao CY,Enzer KG,et al. SIRT1 inactivation evokes antitumor activities in NSCLC through the tu-mor suppressor p27[J]. Mol Cancer Res,2015,13(1):41-49.
[3]
Lin L,Zheng X,Qiu C,et al. SIRT1 promotes endo-metrial tumor growth by targeting SREBP1 and lipoge-nesis[J]. Oncol Rep,2014,32(6):2 831-2 835.
[4]
Biswas SK. Metabolic reprogramming of immune cells in cancer progression[J]. Immunity,2015,43(3):435-449.
[5]
Aquilano K,Vigilanza P,Baldelli S,et al. Peroxisome proliferator-activated receptor gamma co-activator 1al-pha(PGC-1alpha)and sirtuin 1(SIRT1)reside in mito-chondria:possible direct function in mitochondrial bio-genesis[J]. J Biol Chem,2010,285(28):21 590-21 599.
[6]
Zhang W,Tong D,Liu F,et al. RPS7 inhibits colorec-tal cancer growth via decreasing HIF-1α-mediated gly-colysis[J]. Oncotarget,2016,7(5):5 800-5 814.
[7]
Kikuchi K,Noguchi A,Kasajima R,et al. Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma[J]. Tumour Biol,2015,36(10):7 865-7 872.
[8]
Shin DH,Choi YJ,Park JW. SIRT1 and AMPK medi-ate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin[J]. Cancer Res,2014,74(1):298-308.
[9]
Corbet C,Draoui N,Polet F,et al. The SIRT1/HIF2ɑaxis drives reductive glutamine metabolism un-der chronic acidosis and alters tumor response to therapy[J]. Cancer Res,2014,74(19):5 507-5 519.
[10]
Lu J,Tan M,Cai Q. The Warburg effect in tumor pro-gression:mitochondrial oxidative metabolism as an anti-metastasis mechanism[J]. Cancer Lett,2015,356(2):156-164.
[11]
Chung YR,Kim H,Park SY,et al. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype[J]. Hum Pathol,2015,46(7):1 027-1 035.
[12]
Mao B,Hu F,Cheng J,et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepa-tocellular carcinoma[J]. Oncogene,2014,33(11):1 468-1 474.
